Biohaven Just Hurdled An FDA Setback — And Its Moving Lines

Biohaven Just Hurdled An FDA Setback — And Its Moving Lines

Submitted by admin on February 11, 2025 - 9:50pm
Source: 
Investors Business Daily
News Tags: 
Biohaven
FDA
spinocerebellar ataxia
troriluzole
Headline: 
Biohaven Just Hurdled An FDA Setback — And Its Moving Lines
snippet: 

Biohaven (BHVN) stock hurdled its 50-day and 200-day lines Tuesday after the Food and Drug Administration granted its spinocerebellar ataxia treatment a speedier review time.

Do Not Allow Advertisers to Use My Personal information